Unifuzol® in Patients With Peripheral Arterial Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT03861416
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 360 participants
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
- Registry
-
NCT03861416
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT03861416. Randomized; double masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2019-09-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- "Unifuzol®" in Patients With Peripheral Arterial Disease
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- L-arginine 1.4% 500 ml
- Intervention (Drug)
- L-arginine 1.4% 250 ml + placebo 250 ml
- Intervention (Drug)
- Placebo solution
- Lead sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Record details
- Record id
cardio:ct-nct03861416- Content hash
98b154916b48c57845937b28b888f6267adb3969d0d1da683d6f774e1826df68